Alight, Inc. / Delaware
No SEC Form 4 filings for $ALIT in the last 30 days.
See all $ALIT insider activity →Alight, Inc. (ALIT) acquired Abett, a healthcare and benefits data technology company. The deal aims to strengthen Alight's benefits data platform, though financial terms were not disclosed.
ManpowerGroup reported Q2 revenue of $4.86B, up 7.5% YoY, beating estimates. Its stock is up 46% since reporting. Barrett (BBSI) reported $319.3M in revenue, up 3.8% YoY, missing EPS estimates, and its stock is down 21.2%. Alight (ALIT) reported $511M in revenue, down 3.2% YoY, beating expectations but missing guidance, and its stock is down 33.3%. First Advantage (FA) reported $448.8M in revenue, up 14.9% YoY, beating estimates, and its stock is down 3.1%.
Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ALIT (Alight, Inc. / Delaware). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent ALIT coverage spans earnings, mergers & acquisitions and regulation.
The acquisition could enhance Alight's data capabilities and market positioning in benefits technology.
Recap of prior earnings; no new catalyst.
Strategic partnership may broaden Alight's service offering and drive growth.
Partnership expands Alight Worklife’s mental health offering, potentially improving employer engagement and member utilization.
The article frames a near-term earnings beat masking a deteriorating core recurring revenue trend, with Q3 guidance implying continued margin pressure.
AlphAI scores every news story that mentions ALIT with an AI model for sentiment and relevance, and aggregates insider trades from Alight, Inc. / Delaware's SEC EDGAR Form 4 filings. Figures refresh continuously.
Alight, Inc. (ALIT) acquired Abett, a healthcare and benefits data technology company. The deal aims to strengthen Alight's benefits data platform, though financial terms were not disclosed.
1 min readManpowerGroup reported Q2 revenue of $4.86B, up 7.5% YoY, beating estimates. Its stock is up 46% since reporting. Barrett (BBSI) reported $319.3M in revenue, up 3.8% YoY, missing EPS estimates, and its stock is down 21.2%. Alight (ALIT) reported $511M in revenue, down 3.2% YoY, beating expectations but missing guidance, and its stock is down 33.3%. First Advantage (FA) reported $448.8M in revenue, up 14.9% YoY, beating estimates, and its stock is down 3.1%.
2 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readAlight (ALIT) said it partnered with Spring Health to integrate Spring Health’s AI-native mental health services into the Alight Worklife benefits platform. The platform supports over 210 million annual interactions. Alight said the goal is earlier access during events like open enrollment and leave. JAMA Network Open research cited faster recovery for Spring Health members.
3 min readAlight (NYSE:ALIT) reported Q2 revenue of $511 million, beating Wall Street expectations, with adjusted EBITDA of $92 million and free cash flow above estimates. However, recurring revenue fell 4.3% and adjusted EPS dropped to $0.91 from $2.09. Q3 guidance calls for $469 million to $479 million revenue and adjusted EBITDA of $55 million to $61 million.
4 min readAlight (NYSE: ALIT) shares fell about 17% after the company issued weak forward guidance. Although its second-quarter revenue and adjusted profitability beat expectations, investors focused on a 3.2% year-over-year sales decline and a third-quarter revenue outlook about 5.5% below analyst estimates, with a midpoint of $2.09 billion. Full-year revenue and adjusted EBITDA forecasts also missed consensus.
4 min readAlight (NYSE: ALIT) reported Q2 CY2026 revenue of $511 million, down 3.2% year on year but above Wall Street expectations, and non-GAAP EPS of $0.91, 20% above consensus. Next-quarter revenue guidance was $474 million, 5.5% below estimates. Management cited stronger project revenue, but recurring revenue and renewals remain pressured.
5 min readAlight (NYSE:ALIT) reported Q2 CY2026 revenue of $511 million, down 3.2% year on year but 2.8% above Wall Street estimates. Non-GAAP EPS was $0.91, up 20% versus consensus. Guidance for next quarter revenue was $474 million, 5.5% below estimates, and the stock fell 9.1% to $15.58.
4 min readRajgopal Kausik purchased 38 shares of Alight, Inc. / Delaware (ALIT) at $20.53 on 2025-12-15.
2 min readAlight, Inc. / Delaware (ALIT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 2 alit-20260629xexx31xalight.htm EX-3.1 Document Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ALIGHT, INC. Alight, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ Corporation ”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The prese
2 min read
